The purpose of this study is to describe safety and efficacy of Dapaglifozin in adults patients with a systemic right ventricle (congenitally corrected transposition of the great arteries or transposition of the great arteries following arterial switch procedure) and impaired systolic function of the systemic right ventricle.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Adverse Events
Timeframe: 1 year
Nt-proBNP
Timeframe: 1 year
Systemic right ventricle fractional area change
Timeframe: 1 year
Systemic right ventricle global longitudinal strain
Timeframe: 1 year